Merck's Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints

Merck (MRK) announced that its Phase 3 TroFuse-005 trial met primary endpoints of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer. The drug, sacituzumab tirumotecan, showed statistically significant improvements compared to standard chemotherapy.

By Maham Fatima Sat, May 23, 2026 at 3:01 PM GMT+3 2 min read · Yahoo Finance · May 23, 2026, 12:01 UTC

Merck's Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints

Tickers: $MRK

Topics: antibody-drug_conjugate cancer_treatment pharmaceuticals

Read the full article at Yahoo Finance

More World news

Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC
LiveWorld Reports Q3 Revenue of $2.98 Million and GAAP EPS of -$0.01 Seeking Alpha · November 12, 2026, 16:37 UTC
Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC
Rising New Vehicle Monthly Payments Pose Affordability Risks for Ford and General Motors Motley Fool · November 12, 2026, 16:33 UTC
SpaceX Shares Rise Following Nvidia CEO Jensen Huang Resignation Motley Fool · November 12, 2026, 16:34 UTC
tZERO Receives CFTC Approval for Derivatives Exchange and Clearing Operations PR Newswire · November 12, 2026, 16:36 UTC
enGene Therapeutics Shares Surge Following Positive Mid-Stage Trial Data and Piper Sandler Upgrade Seeking Alpha · November 12, 2026, 16:33 UTC
Former Nvidia CEO Jensen Huang to Testify Before Congress Regarding Export Controls and Security Concerns TechCrunch · November 12, 2026, 16:36 UTC
Nobu Hospitality and Infracorp Partner to Develop Luxury Destination in Bahrain PR Newswire · November 12, 2026, 16:34 UTC